Initiative Aims to Boost Clinical Trial Participation Among Asian-Americans
OncLive: Monday, December 16, 2013
Asian-Americans are the only racial group for whom cancer is the leading cause of death. Consequently, some Asian-American populations suffer disproportionately from certain types of cancer, including those that are largely preventable.
The UC Davis Comprehensive Cancer Center and the National Cancer Institute (NCI)-funded National Center for Reducing Asian American Cancer Health Disparities are working to address these disparities through programs to boost participation in clinical trials, collect biospecimens, and conduct blood genomics research.
Asian-Americans have extremely low participation rates in cancer clinical trials. Language barriers, mistrust of the medical system, and other cultural dynamics often create misunderstandings about the nature and purpose of cancer trials, discouraging participation and leading to underrepresentation of Asian-Americans. Read More